Rybelsus vs Ozempic: Oral vs Injectable Semaglutide, Compared Honestly

A pharmacist told me recently that the most common question at her counter this winter is not about a drug at all, but about a form. “Is the pill as good as the shot?” The question has a date attached. In December 2025 the FDA approved a higher-strength oral semaglutide for chronic weight management, the first GLP-1 tablet cleared for that purpose, and, as of early 2026, search interest in rybelsus vs ozempic has climbed with it. People who had quietly ruled out injections are suddenly curious about swallowing the same molecule instead.

The comparison deserves a straight answer rather than a shrug, because the two products are more alike than their marketing suggests and more different than their shared ingredient implies. Rybelsus has existed since 2019 and never became a household name. Ozempic became a cultural shorthand. The reason sits in chemistry, in trial data and in the small daily rituals a tablet demands.

What follows is the version of this comparison a careful clinician would give you over a long appointment: what each form is approved to do, what the trials measured, how firm the numbers are, and where the honest gaps remain.

Is Rybelsus the same as Ozempic?

Chemically, yes. Both contain semaglutide, a laboratory-made copy of a gut hormone called GLP-1 (glucagon-like peptide-1), which the body releases after eating to prompt insulin, slow stomach emptying and signal fullness to the brain. Medicines in this class are called GLP-1 receptor agonists, meaning they switch on the same receptors the natural hormone uses, but linger in the body far longer.

The resemblance ends at the delivery route. Ozempic is a liquid injected under the skin once a week, usually in the abdomen, thigh or upper arm. Rybelsus is a tablet taken by mouth every day. That single difference changes how much drug reaches the bloodstream, how stable the blood level stays through the week, what the label demands of the person taking it, and which trials were run to prove each one works.

Their approved uses overlap but are not identical. Both are FDA-approved to improve blood sugar in adults with type 2 diabetes alongside diet and exercise. Ozempic also carries approvals to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease, and, since January 2025, to slow kidney disease progression in that population. Rybelsus gained its own cardiovascular risk-reduction indication in late 2025 after a dedicated outcomes trial. Neither is approved for weight loss as a standalone goal; a separate semaglutide brand holds that indication.

So when a search box asks whether the two are “the same,” the accurate reply is: same medicine, different vehicle, different evidence base, and a different set of rules for taking it. The rest of this article unpacks each of those differences in turn.

What changed recently to make rybelsus vs ozempic a hot search

Three dated events pushed this comparison back into public view, and each one is traceable in the labeling and trial literature summarized by MedlinePlus and Mayo Clinic.

First, in January 2025 the FDA expanded Ozempic’s label to include reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The approval rested on the FLOW trial, in which about 3,500 participants were followed for roughly three years and the semaglutide group saw a 24 percent relative reduction in a combined kidney and cardiovascular endpoint. It was the first GLP-1 medicine to earn a kidney indication.

Second, in March 2025 the SOUL trial was published, the first large cardiovascular outcomes study of oral semaglutide. More than 9,600 adults with type 2 diabetes and existing heart, kidney or vascular disease were followed for a median of about four years. The tablet reduced major adverse cardiovascular events (heart attack, stroke or cardiovascular death) by 14 percent relative to placebo. The FDA added a cardiovascular indication to Rybelsus later in 2025 on the strength of that result.

Third, in December 2025 the FDA approved a higher-strength oral semaglutide tablet for chronic weight management, based on a 64-week trial in adults with obesity in which average weight loss was roughly 13 percent versus about 2 percent on placebo. That product is a different brand and strength from Rybelsus, but it answered the lingering question of whether a swallowed GLP-1 could rival the injected one for weight.

Put together, the tablet form of semaglutide now has outcome data it lacked for six years. That is genuinely new, and it reframes the old assumption that “the pill is the weaker cousin.”

Oral semaglutide vs injection: how each form actually gets into the body

Semaglutide is a peptide, a short chain of amino acids. Swallow a peptide and the stomach treats it like any protein: acid and enzymes break it down before it can be absorbed. Insulin has never been a pill for exactly this reason. Rybelsus gets around the problem with an absorption enhancer called SNAC (salcaprozate sodium), a compound co-formulated in the tablet that briefly raises the pH around it and helps semaglutide slip across the stomach lining.

The trick works, but inefficiently. Only about one percent of the semaglutide in the tablet reaches the bloodstream, according to the pharmacology summarized in prescribing information. That is why the oral form is taken daily rather than weekly, and why the label is unusually strict about how. The tablet must be swallowed on an empty stomach with a small amount of plain water, followed by a waiting period of roughly half an hour before any food, drink or other medicines. Food in the stomach, a large glass of water, or a coffee taken too soon can cut absorption sharply.

An injection skips the digestive tract entirely. Semaglutide placed under the skin forms a small depot that releases slowly, and the molecule’s design, which binds to the blood protein albumin, gives it a half-life of about a week. Blood levels stay comparatively steady between doses; there is no empty-stomach rule and no interaction with breakfast.

Neither route is “better” in the abstract. One trades a needle for a daily ritual with real consequences if skipped; the other trades the ritual for a weekly injection and a refrigerated pen. Understanding this mechanism explains most of the differences that follow, from trial results to the reasons Rybelsus never caught on.

Rybelsus vs Ozempic for blood sugar: what the diabetes trials show

Each product earned its diabetes approval through its own clinical trial program, and the two were never tested head to head at their approved strengths. Comparisons are therefore indirect, which matters when reading the numbers below.

Ozempic’s program, the SUSTAIN trials, enrolled thousands of adults with type 2 diabetes across more than ten studies. The headline measure was HbA1c, a blood test that reflects average blood sugar over roughly three months. Across SUSTAIN, semaglutide injection typically lowered HbA1c by about 1.5 to 1.8 percentage points from baseline over 30 to 56 weeks, outperforming placebo, several older diabetes drugs and other GLP-1 injections it was compared against.

Rybelsus’s program, the PIONEER trials, ran a similar design with the tablet. Reductions in HbA1c were generally in the range of 1.0 to 1.4 percentage points, depending on the strength studied and the comparator. In PIONEER 4, oral semaglutide was compared directly with a daily GLP-1 injection from a different manufacturer and matched it on HbA1c at 26 weeks. In PIONEER 3 it beat a widely used oral diabetes drug from the DPP-4 inhibitor class.

Both sets of results are randomized, placebo- or active-controlled trials, which is the highest grade of evidence for a medicine’s effect. The injection’s average reductions were modestly larger, and the gap is consistent with the lower and more variable absorption of the tablet.

For an individual, a difference of a few tenths of a percentage point in HbA1c may or may not be clinically meaningful; it depends on where blood sugar started, what other medicines are in use and what target the clinician has set. The trials tell us what happened on average to large groups. They cannot tell any one reader which form will control their blood sugar better.

Rybelsus vs Ozempic weight loss: the honest numbers, and is Ozempic stronger?

Weight loss was a secondary outcome in both diabetes programs, not the goal, and the trials enrolled people with type 2 diabetes rather than people seeking to lose weight. With that caveat, the pattern is clear and consistent across studies.

In the SUSTAIN trials, participants on Ozempic lost on average about 4 to 6 kilograms (roughly 9 to 13 pounds) over 30 to 56 weeks. In the PIONEER trials, participants on Rybelsus lost about 2 to 4 kilograms (roughly 4 to 9 pounds) over similar periods. People with diabetes tend to lose less weight on GLP-1 medicines than people without it, so both figures are lower than the numbers that made semaglutide famous.

Those famous numbers come from different trials of different strengths. The STEP 1 trial of the injectable weight-management brand reported about 15 percent body-weight loss at 68 weeks versus about 2.4 percent on placebo. The 2025 trial that led to the oral weight-management approval reported roughly 13 percent at 64 weeks. Read side by side, these suggest that at higher strengths the tablet closes most of the gap with the injection, though again no trial randomized people between the two.

So, is Ozempic “stronger” than Rybelsus? At their approved diabetes strengths, the injection delivers more semaglutide to the bloodstream more consistently and produced larger average weight and HbA1c changes. Strength here is about exposure and reliability, not a different drug. A tablet taken perfectly every morning may track closer to the injection than the averages imply; one taken with coffee will not.

Neither Rybelsus nor Ozempic is approved for weight loss in people without diabetes. Any use for that purpose is off-label and a decision for the treating clinician, discussed further below.

Heart and kidney protection: where the injection had a six-year head start

For many adults with type 2 diabetes, the question that matters most is not weight or HbA1c but whether a medicine lowers the chance of a heart attack, stroke or kidney failure. Here the two forms of semaglutide have very different histories, and the gap only recently narrowed.

Ozempic’s cardiovascular evidence dates to SUSTAIN 6, published in 2016 with about 3,300 participants who had type 2 diabetes and high cardiovascular risk. Over roughly two years, major adverse cardiovascular events fell by 26 percent relative to placebo, driven mainly by fewer non-fatal strokes. The result led to the 2020 FDA indication. The FLOW trial then added kidney outcomes in 2024, with a 24 percent relative reduction in a combined endpoint of kidney failure, major loss of kidney function and death from kidney or cardiovascular causes.

Rybelsus had no comparable outcome trial for its first six years. The PIONEER 6 study, required for approval, was designed only to show the tablet did not increase cardiovascular risk, and it did not. Whether it actively reduced risk remained unknown until the SOUL trial reported in March 2025: a 14 percent relative reduction in major cardiovascular events over about four years in more than 9,600 people with established disease. The FDA added a cardiovascular indication to the Rybelsus label later that year.

The two trials are not directly comparable. SOUL enrolled a sicker, older population already taking many protective drugs, which tends to shrink the measurable benefit of any new one. Expert commentary on both trials, summarized by Cleveland Clinic and others, treats them as evidence that semaglutide’s heart benefit is a property of the molecule rather than the needle.

For kidney protection specifically, only the injection currently carries the indication. That is a labeling fact, not a verdict that the tablet lacks the effect; the tablet simply has not been tested for it in a dedicated trial.

Rybelsus side effects vs Ozempic side effects: same list, different rhythm

Because the active molecule is identical, the side-effect profiles are nearly identical too. The most common complaints with both, documented across the SUSTAIN and PIONEER programs and listed by MedlinePlus and the NHS, are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite and belching. Nausea affected roughly one in five participants on either form in the diabetes trials, usually most intense in the first weeks and when strength was increased, then fading for most people.

The rhythm differs. A weekly injection produces a steady drug level with a gentle rise after each dose, and many people describe a predictable pattern of queasiness in the day or two after injecting. A daily tablet produces a smaller daily pulse, and the empty-stomach rule means the drug arrives when the stomach is already empty, which some people find sharpens morning nausea. Neither pattern is universal.

Both labels carry the same serious warnings. In rodent studies semaglutide caused thyroid C-cell tumors; it is not known whether this applies to humans, and both products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or a rare inherited syndrome called MEN 2. Both list pancreatitis (inflammation of the pancreas), gallbladder disease, acute kidney injury from dehydration, worsening of diabetic eye disease in some people, and low blood sugar when combined with insulin or sulfonylureas. The injection adds injection-site reactions; the tablet adds nothing unique beyond its absorption constraints.

Discontinuation rates due to side effects in the diabetes trials were broadly similar, in the range of about 5 to 11 percent for both forms, against roughly 3 to 5 percent on placebo. The honest summary: choosing the tablet to avoid side effects is not supported by the data; choosing it to avoid a needle is.

What is the downside of Rybelsus?

The tablet’s chief drawback is not a side effect. It is the discipline the label demands every single morning, and what happens when life interferes.

Consider the routine. The tablet is taken first thing on waking, with a small sip of plain water, before anything else. Then comes the wait, about half an hour, before breakfast, coffee, juice, a thyroid pill or a blood pressure tablet. Take it with a full glass of water and absorption drops. Take it after a bite of toast and much of the dose is wasted. The pharmacology studies behind the label showed that these small deviations can cut blood levels substantially, which is why the instructions are more rigid than for almost any other oral diabetes medicine.

Several practical consequences follow. People who take other morning medicines must reorganize their schedule, and some, such as certain thyroid replacements, have their own empty-stomach rules that now compete. Shift workers with irregular waking times find consistency hard. Anyone who travels across time zones has to think about it. A weekly injection asks for one decision every seven days; the tablet asks for a correct decision every day, roughly 365 times a year.

There is also the matter of variability. Even when taken correctly, absorption of oral semaglutide varies more from person to person and day to day than the injection does, which is part of why average trial effects were smaller.

None of this makes Rybelsus a poor medicine. For someone who cannot or will not inject, a correctly taken tablet delivers the same molecule with proven blood-sugar and, now, cardiovascular benefit. It simply shifts the burden from the needle to the clock, and that burden suits some lives far better than others. A frank conversation with the prescriber and pharmacist about morning habits is the single most useful step before starting it.

Why is Rybelsus not popular?

Rybelsus arrived in 2019 as a genuine scientific achievement: the first oral peptide hormone medicine approved in the United States. Yet it never approached the recognition of the injection it followed. The reasons are a mix of pharmacology, timing and indication, and none of them is a secret.

Start with potency at the approved strengths. The tablet’s modest absorption translated into smaller average effects on weight in the diabetes trials, and weight, not HbA1c, is what drove public interest in semaglutide from 2021 onward. People searching for the medicine behind the headlines were searching for the injection’s numbers.

Then there is indication. For six years Rybelsus was approved only for blood sugar in type 2 diabetes. It had no cardiovascular claim until late 2025, no kidney claim, and no weight-management version until a separate higher-strength tablet was approved in December 2025 under a different brand. Clinicians following guidelines that prioritize proven heart and kidney protection naturally reached for the product with the outcome trials behind it.

The daily routine, described above, discouraged both prescribers and patients. Guidance from the NHS and Mayo Clinic emphasizes that the tablet must be taken exactly as directed to work, a sentence that does not appear on most diabetes medicines.

Finally, timing. The injection launched first, accumulated the trials first and became the default in clinical habit. By the time the tablet had comparable outcome data, the shorthand was already set.

Is that unpopularity deserved? Partly. The tablet is less potent at its diabetes strengths and more demanding to take. But the 2025 data showing cardiovascular benefit, and the proof that higher-strength oral semaglutide can produce double-digit weight loss, suggest the reputation lagged the science. Popularity and evidence are not the same thing, and this is a case where they drifted apart.

Rybelsus vs Ozempic side by side

The table below condenses the approved-label facts and the main trial findings. Figures are averages from randomized trials in adults with type 2 diabetes unless stated otherwise, and the two products were not compared directly in any trial.

Feature	Rybelsus (oral semaglutide)	Ozempic (semaglutide injection)
Form and frequency	Tablet, taken daily	Pre-filled pen, injected weekly
FDA approval year	2019	2017
Approved uses	Type 2 diabetes blood sugar; cardiovascular risk reduction (added 2025)	Type 2 diabetes blood sugar; cardiovascular risk reduction (2020); kidney disease in type 2 diabetes (2025)
Typical HbA1c change in pivotal trials	About 1.0 to 1.4 percentage points	About 1.5 to 1.8 percentage points
Typical weight change in diabetes trials	About 2 to 4 kg	About 4 to 6 kg
Cardiovascular outcome trial	SOUL (2025): 14% relative reduction in major events	SUSTAIN 6 (2016): 26% relative reduction in major events
Kidney outcome trial	None dedicated	FLOW (2024): 24% relative reduction
Key administration rule	Empty stomach, small sip of water, wait before food or other medicines	Any time of day, with or without food; rotate injection sites
Storage	Room temperature	Refrigerate before first use
Most common side effects	Nausea, diarrhea, constipation, abdominal pain, reduced appetite	Same, plus injection-site reactions
Approved for weight loss alone?	No	No

Two cautions when reading it. The cardiovascular percentages come from trials with different populations and durations, so a larger number does not prove a stronger drug. And every row describes group averages; the person taking the medicine is not an average.

What the evidence actually says, graded by strength

Claims about these two medicines arrive with very different pedigrees. Sorting them by the quality of evidence behind each is more useful than any single verdict.

Strong evidence (multiple randomized controlled trials). Both forms lower HbA1c in type 2 diabetes. Both produce modest average weight loss in people with diabetes. Both reduce major cardiovascular events in people with type 2 diabetes and established cardiovascular or kidney disease, shown in SUSTAIN 6 for the injection and SOUL for the tablet. Gastrointestinal side effects are common with both and usually ease over time. These findings rest on tens of thousands of trial participants and are the firmest statements in this article.

Strong for one form only. Kidney protection has been demonstrated in a randomized trial only for the injection (FLOW). Double-digit percentage weight loss in people with obesity has been shown in randomized trials for both routes, but at higher strengths and under different brands than Rybelsus or Ozempic.

Moderate evidence (indirect comparison). That the injection is more potent than the tablet at approved diabetes strengths. No trial randomized people between Rybelsus and Ozempic. The conclusion comes from comparing separate trials with similar designs, which is reasonable but weaker than a head-to-head study.

Expert opinion or pharmacology, not outcome data. That real-world adherence favors the weekly injection over the daily tablet. Observational prescription data lean this way, but such data cannot separate the effect of the medicine from the habits of the people choosing it. Likewise, the idea that the tablet is “gentler” on the stomach is a plausible-sounding inference that the trials do not support.

Unknown. Whether one form is safer over decades. Semaglutide has been in wide use for less than ten years. Long-term registries are ongoing; honest clinicians say so.

Common myths about Rybelsus and Ozempic, corrected

Viral claims about these medicines travel faster than trial results. Here are the ones that circulate most, set against what the evidence shows.

“The pill is just a weaker version for people scared of needles.” Partly true, mostly outdated. At diabetes strengths the tablet does deliver less drug on average. But the 2025 SOUL trial showed the oral form reduces cardiovascular events, and a higher-strength oral semaglutide produced roughly 13 percent weight loss in a 64-week trial. Weaker at a given strength is not the same as ineffective.

“Rybelsus has fewer side effects because it is oral.” Not supported. The PIONEER and SUSTAIN trials report the same gastrointestinal effects at comparable rates. The molecule, not the route, drives them.

“You can take Rybelsus with breakfast if you take it a bit later.” False and consequential. Food in the stomach sharply reduces absorption. The empty-stomach rule is not a suggestion; it is the condition under which the trials were run and the label was written.

“Ozempic is approved for weight loss.” It is not. Ozempic is approved for type 2 diabetes, cardiovascular risk reduction and kidney disease in type 2 diabetes. A separate semaglutide brand holds the weight-management indication. Use of Ozempic or Rybelsus for weight alone is off-label.

“Any semaglutide labeled ‘compounded’ or ‘research grade’ is the same thing.” No. Compounded semaglutide is not FDA-approved, has not been tested in the trials described here, and the FDA has warned about dosing errors and unverified ingredients. Products sold as “research peptides” are not approved medicines and are not for human use. Neither should be obtained or used outside a prescriber’s care.

“Once you stop, the weight all comes back, so it never worked.” Weight regain after stopping is well documented in extension studies and reflects how appetite hormones behave, not a failure of the medicine. It is a reason for long-term planning with a clinician, not a myth about effectiveness.

Which form fits whose life? A decision the prescriber makes with you

Trial averages describe populations. The choice between a daily tablet and a weekly injection is made one person at a time, and the factors that tilt it are often not the ones that dominate online debate.

Indication comes first. A person with type 2 diabetes and chronic kidney disease has a labeled kidney benefit only with the injection. A person with established heart disease now has a labeled cardiovascular benefit with either. Someone whose main goal is weight management without diabetes falls outside both labels, and the clinician will weigh the off-label evidence described above against the alternatives that are approved for that purpose.

Daily habits come next. Someone who already takes a morning medicine on an empty stomach, wakes at irregular hours or cannot reliably wait before coffee is at real risk of under-absorbing the tablet. Someone who travels without refrigeration, or who has a strong aversion to self-injection, may find the tablet the only form they will actually take. Adherence research across many conditions shows that the medicine a person takes consistently outperforms the stronger one they skip.

Other medicines matter. The tablet’s absorption can be affected by what else is swallowed in that morning window, and a pharmacist review is worth the time. Both forms slow stomach emptying and can alter how other oral drugs are absorbed, a point the NHS and Mayo Clinic guidance both flag.

Finally, history. A personal or family history of medullary thyroid cancer or MEN 2 rules out both. Past pancreatitis, gallbladder disease, severe gastrointestinal disorders or diabetic retinopathy prompt caution with either.

Nothing here should be read as a recommendation to start, switch or stop. Switching between the two forms is not a simple swap; strengths do not correspond one to one, and the transition is managed by the prescriber. If a reader is weighing the two, the most productive next step is to bring this list of practical questions to that appointment.

When to see a doctor

Most people on either form of semaglutide experience nothing worse than passing nausea or a change in bowel habit. A smaller number develop problems that need prompt medical attention, and the warning signs are the same for the tablet and the injection. The lists below reflect the labeling summarized by MedlinePlus, Mayo Clinic and the NHS.

Seek urgent care, or call emergency services, for:

• Severe, persistent pain in the upper abdomen, especially if it spreads to the back and comes with vomiting; this can signal pancreatitis.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or clay-colored stools, which may indicate gallbladder disease.
• Vomiting or diarrhea severe enough that you cannot keep fluids down, with dizziness, very dark urine or passing little urine; dehydration can injure the kidneys.
• Symptoms of a serious allergic reaction: swelling of the face, lips, tongue or throat, trouble breathing, or widespread rash.
• A lump or swelling in the neck, hoarseness that does not go away, or trouble swallowing.
• Symptoms of severe low blood sugar if you also take insulin or a sulfonylurea: confusion, shakiness, sweating, fainting.

Contact the prescribing clinician soon, without stopping the medicine on your own, for:

• Any new change in vision, blurring or dark spots, particularly if you have known diabetic eye disease.
• Nausea or vomiting that does not settle after the first weeks or that interferes with eating and drinking.
• Unintended rapid weight loss, persistent low mood, or new thoughts of self-harm.
• Difficulty following the tablet’s empty-stomach routine, or missed injections; the clinician may adjust the plan rather than let effectiveness quietly slip.
• Planning a pregnancy or finding out you are pregnant; both labels advise stopping well before conception, and that timing is set by the clinician.

Any decision to start, pause, switch or stop semaglutide in either form belongs with the prescribing clinician, who knows the full history and the other medicines involved.

Frequently asked questions

Is Rybelsus the same as Ozempic?

They contain the same active drug, semaglutide, but are different products. Rybelsus is a daily tablet; Ozempic is a weekly injection. Both are approved for type 2 diabetes, and both now carry cardiovascular risk-reduction indications, while only Ozempic is approved for kidney disease in type 2 diabetes. Their strengths do not correspond one to one, so they are not interchangeable without a prescriber managing the change.

Is Ozempic stronger than Rybelsus?

At their approved diabetes strengths, yes, in the sense that the injection delivers more semaglutide to the bloodstream more consistently and produced larger average reductions in HbA1c and weight in trials. The difference comes from absorption, not a different medicine. Higher-strength oral semaglutide, approved under a separate brand in December 2025, narrows that gap considerably for weight management.

Can you lose weight with Rybelsus?

In diabetes trials, people taking Rybelsus lost on average about 2 to 4 kilograms over roughly a year, less than with the injection. Rybelsus is not approved for weight loss, and using it for that purpose alone is off-label. Whether it is appropriate for an individual, and whether an approved weight-management medicine would be a better fit, is a decision for the treating clinician.

What is the downside of Rybelsus?

The main drawback is the strict daily routine. It must be taken on an empty stomach with a small sip of water, followed by a waiting period before any food, drink or other medicines; deviations can sharply reduce absorption. It also had less potent average effects than the injection in trials and, until 2025, lacked the outcome data the injection had accumulated.

Why is Rybelsus not popular?

Several factors converged: smaller average weight and blood-sugar effects at diabetes strengths, a demanding empty-stomach routine, no cardiovascular or kidney indication for its first six years, and the fact that the injection launched first and became the clinical default. The 2025 SOUL trial and the approval of a higher-strength oral semaglutide suggest its reputation lagged behind the evidence.

What are the main Rybelsus side effects compared with Ozempic?

The lists are nearly identical because the molecule is the same: nausea, vomiting, diarrhea, constipation, abdominal pain and reduced appetite, affecting roughly one in five people early on. Both carry warnings about pancreatitis, gallbladder disease, thyroid C-cell tumors seen in animals, kidney injury from dehydration and eye complications. The injection adds injection-site reactions; the tablet adds no unique side effects.

Does oral semaglutide vs injection make a difference for heart protection?

Both forms have now shown cardiovascular benefit in randomized trials. The injection reduced major cardiovascular events by 26 percent in SUSTAIN 6; the tablet reduced them by 14 percent in the larger, longer SOUL trial published in 2025. The populations differed, so the numbers are not directly comparable, but expert commentary treats the benefit as a property of semaglutide itself.

Can you switch from Ozempic to Rybelsus or back?

Switching is possible but is not a simple swap, because the tablet and injection strengths do not match one to one and absorption differs. The prescriber decides whether a switch makes sense, how to time it and how to monitor blood sugar during the transition. Changing form on your own, or sharing medicine between the two routes, is not safe.

Why does Rybelsus have to be taken on an empty stomach?

Semaglutide is a peptide that the stomach would normally digest. Rybelsus includes an absorption enhancer called SNAC that helps a small fraction cross the stomach lining, but only when the stomach is empty and the drug is not diluted by much water or mixed with food. Taking it with breakfast or coffee can reduce the amount absorbed substantially.

Is compounded semaglutide the same as Rybelsus or Ozempic?

No. Compounded semaglutide is not FDA-approved, has not been studied in the trials that support Rybelsus and Ozempic, and the FDA has reported adverse events linked to dosing errors and unverified ingredients. Products sold as ‘research peptides’ are not approved for human use at all. Neither should be obtained or used outside the care of a licensed prescriber.

References

• MedlinePlus: Semaglutide Injection
• NHS: Semaglutide (Ozempic, Rybelsus, Wegovy)
• Cleveland Clinic: GLP-1 Agonists

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.